Cardiovascular

A study has found that both recreational and non-recreational activity reduces the risk of mortality and cardiovascular disease, regardless of the country's economic status.

Excessively low levels of low-density lipoprotein cholesterol and triglycerides is associated with a higher all-cause mortality among American Indians, according to a new study published online ahead of print in Journal of Diabetes and Its Complications.

Current drugs for pulmonary hypertension treat 3 pathways, but currently there aren't any new drugs to treat different pathways, although there likely will be some in the future, said Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.

There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.

Experts said that the frequency and quality of social relationships have a greater effect on mortality than obesity or drinking alcohol, and this commands attention from health systems.

In the wake of Hurricane Harvey, Houston is expected to face a host of health challenges, including air pollution. Here are 5 facts about how air pollution affects people’s health.

The use of statin drugs in patients with chronic obstructive pulmonary disease is associated with benefits including decreased lung-related and all-cause mortality, according to a research.

Researchers have known for years: what happens to mom in pregnancy affects the baby. That holds true with prenatal exposure to air pollution, which has lingering cardiovascular effects, such as birth defects and a higher risk of obesity, explained Jeanette Stingone, PhD, of Mount Sinai Health System.

This week, the top managed care stories included responses to the disaster in Houston after Hurricane Harvey; the approval of the first gene therapy in the United States; and a new cardiovascular indication for a popular drug to treat type 2 diabetes.

The study finds that the GLP-1 receptor agonist can slow progression of kidney disease, one of the most costly and debilitating complications of type 2 diabetes.

The findings will likely add to the controversy over the US dietary guidelines. Lobbyists for grain interests have long been accused of having undue influence in food policy, especially over the now-discarded "food pyramid."

The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care, said John Eikelboom, MBBS, MSc, FRCPC, associate professor at McMaster University.

The results of the COMPASS trial testing rivaroxaban plus aspirin in patients with coronary artery disease or peripheral artery disease showed such significant benefits for reducing ischemic events that it was stopped early, explained Deepak Bhatt, MD, MPH, of Brigham and Women's Hospital and Harvard Medical School.

For each level of cardiovascular risk, lifestyle factors remain a significant contributor that can be modified to reduce risk. However, some risk will remain nonmodifiable and require therapy, according to panelists during a session on cardiovascular prevention at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

Rivaroxaban plus aspirin has significant benefits for patients with peripheral artery disease (PAD) and stable coronary artery disease, according to the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.

Novo Nordisk announced that its diabetes drug liraglutide (Victoza) has been approved by the FDA for a new indication: it can reduce the risk of major cardiovascular (CV) events in patients with type 2 diabetes (T2D) and existing CV disease.

The connection between diabetes and cardiovascular disease is well-known, but a new study gets at the mechanism of how this occurs.

The review reports that fewer than 50% of patients with diabetes are being treated according guidelines to prevent a cardiovascular event.

Patients with congenital heart defects, such as Marfan syndrome (MFS), are experiencing longer life expectancies due to new advances in medicine-resulting in a greater need for medical rehabilitation.

The reduced mortality risk was not seen in patients who did not have diabetes before surgery. But in those who did, the results were dramatic.

Patients often stop statin treatment following an adverse reaction; however, new research finds an association between continued statin prescriptions after an adverse reaction and a decreased incidence of death and cardiovascular events.

Many accountable care organizations participating in the Medicare Shared Savings Program focus on disease control and medication use, but a new study published in JAMA Cardiology has found that the programs have not made any meaningful changes in medication use or adherence.

Coverage from the first of 3 Peer Exchangeâ„¢ discussions from the Diabetes Stakeholders Summit.

There is an association between the presence of cardiovascular risk factors in adolescence and a lower cognition later in life, regardless of the exposure experienced during adulthood.